undamentalytics Newsletter
Sign in

Mangoceuticals, Inc. income statement

In fiscal 2025, Mangoceuticals, Inc. reported revenue of $456,021, down 26.0% on the year before, operating income of −$18.0m (a -3954.3% margin) and net income of −$20.6m, or −$2.17 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue01100
Cost of revenue00000
Gross profit00000
General and administrative23342
Operating income−2−9−8−18−12
Interest expense0−000—
Income before tax−2−9−9−21−15
Net income−2−9−9−21−15
Diluted EPS−$0.57−$1.72−$0.96−$2.17—
Diluted shares (average)4m5m10m10m—
EBITDA−2−9−8−18−12

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ATPC vs MGRXAHG vs MGRXAMS vs MGRX

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Mangoceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mangoceuticals, Inc.